Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease

Vascular and Endovascular Surgery

Volumn 41, Issue 6, 2008, Pages 506-508

  Schild, A Frederick ^a   Perez, Eduardo A ^a   Gillaspie, Erin ^a   Patel, Asha R ^a   Noicely, Karlene ^a   Baltodano, Neyton ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

End stage renal disease; HIV; Infection; Patency; Thrombosis; Vascular access; Vectra

Indexed keywords

POLITEF; POLYETHERURETHAN; POLYETHERURETHANUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANNULATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIALYSIS; FEMALE; GRAFT INFECTION; GRAFT PATENCY; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANTATION; INFECTION RATE; KIDNEY FAILURE; MALE; PATIENT SAFETY; POLITEF IMPLANT; VASCULAR ACCESS;

ADULT; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HEMATOMA; HIV SEROPOSITIVITY; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; POLYURETHANES; PROSTHESIS DESIGN; PROSTHESIS-RELATED INFECTIONS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 37249041632     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574407308208     Document Type: Article

References (10)

1. Ahuja TS, O'Brien WA Special issues in the management of patients with ESRD and HIV infection. Am J Kidney Dis. 2003 ; 41: 279-291.
2. Mokrzycki MH, Schroppel B., von Gersdorff G., Rush S., Zdunek MP, Feingold R. Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. J Am Soc Nephrol. 2000 ; 11: 2122-2127.
3. Rao Tks. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial. 2003 ; 16: 233-244.
4. Mailloux LU, Bellucci AG, Wiles BM, et al. Mortality in dialysis patients: analysis of causes of death. Am J Kidney Dis. 1991 ; 18: 3326-3335.
5. Nassar GM, Ayus JC Infectious complications of the hemodialysis access. Kidney Int. 2001 ; 60: 1-13.
6. Schild AF, Simon S., Prieto J., Raines J. Single-center review of infections associated with 1574 consecutive vascular access procedures. Vasc Endovasc Surg. 2003 ; 37: 27-31.
7. Brock JS, Sussman M., Wamsley M., Mintzer R., Baumann FG, Riles TS The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. J Vasc Surg. 1992 ; 16: 904-910.
8. Curi MA, Pappas PJ, Silva MB, et al. Hemodialysis access: influence of the human immunodeficiency virus on patency and infection rates. J Vasc Surg. 1999 ; 29: 608-616.
9. Anderson JE, Chang AS, Anstadt MP Polytetrafluoroethylene hemo-access site infections. ASAIO J. 2000 ; 46: S18 - S21.
10. Glickman MH, Stokes GK, Ross JR, et al. Multicenter evaluation of a polytetrafluoroethylene vascular access graft as compared with the expanded polytetrafluoroethylene vascular access graft in hemodialysis applications. J Vasc Surg. 2001 ; 34: 465-473.